Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it.

Autor:	Padilla-Martínez EM; Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia., Romero-Sanchez C; Department of Rheumatology and Immunology, Grupo de Inmunología Clinica Aplicada, School of Medicine, Hospital Militar Central/ Universidad Militar Nueva Granada, Bogota, Colombia., Bello-Gualtero JM; Department of Rheumatology and Immunology, Grupo de Inmunología Clinica Aplicada, School of Medicine, Hospital Militar Central/ Universidad Militar Nueva Granada, Bogota, Colombia., Mesa-Betancourt AM; Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia., Bautista-Molano W; Department of Rheumatology and Immunology, Grupo de Inmunología Clinica Aplicada, School of Medicine, Hospital Militar Central/ Universidad Militar Nueva Granada, Bogota, Colombia., Valle-O R; Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia.
Jazyk:	angličtina
Zdroj:	Current rheumatology reviews [Curr Rheumatol Rev] 2019; Vol. 15 (4), pp. 329-335.
DOI:	10.2174/1573397115666190708113601
Abstrakt:	Background: Many patients may have resistance to TNF-blockers. These drugs may induce neutralizing antibodies. The determination of the drug levels of TNF-blockers and Anti-Drug Antibodies (ADAs) against TNF-blockers may help to make clinical decisions. Objectives: The objective of this study was to associate and predict the drug levels of TNFblockers and ADAs in relation to disease activity in patients with Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA). Methods: Cross-sectional study including patients fulfilling ASAS classification criteria for SpA and 2010 ACR-EULAR classification criteria for RA. These patients were treated with Adalimumab (ADA), Infliximab (IFX), and Etanercept (ETN). A bivariate analysis and the chi-square test were performed to evaluate the association of ADAs and drug levels with activity measures for SpA and RA. Five regression models analyzing drug levels, ADAs and disease activity measures using a multiple linear regression were performed in order to evaluate the prediction of ADAs and drug levels in relation to disease activity. Results: In SpA, IFX levels were associated with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (p=0.034). In RA, total drug levels were associated with DAS28-ESR (28 joint Disease activity Score-erythrocyte sedimentation rate), (p=0.008), DAS28-CRP (p=0.042), CDAI (Clinical Disease Activity Index) (p=0.047) and SDAI (Simple Disease activity index), (p=0.017). ADA levels had association with CDAI (p=0.002) and SDAI (p=0.002). IFX levels were associated with a DAS28-ESR (p=0.044), DAS28-CRP (p=0.022) and SDAI (p=0.022). ADAs were associated in SpA with BASDAI (p=0.027). Drug levels and ADAs did not predict disease activity in patients with SpA or RA. Conclusion: ADAs and drug levels of anti-TNF are associated with disease activity measures in patients with SpA and RA. However, they cannot predict clinical activity in these conditions. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu